Review article: approaches to Barrett's oesophagus treatment-the role of proton pump inhibitors and other interventions.
Despite implementation of screening and surveillance strategies, a significantly large number of patients with Barrett's oesophagus remain undiagnosed. In those who are identified, the management options include acid reduction therapies with proton pump inhibitors or anti-reflux surgery. Endoscopic ablative therapies have also been attempted. In addition to having inherent procedure-related risks with ablative therapies, these alternatives may be limited by high rates of failure, need for continued acid suppressive therapy, metaplasia persistence under otherwise normal appearing tissue, need for procedural expertise, and continued risk for adenocarcinoma development. Therefore, a widely applicable chemoprevention strategy that cost-effectively reduces the rate of progression from oesophagitis to adenocarcinoma in high-risk patients and perhaps those at lower rates of risk is highly desirable. The AspECT trial currently underway is seeking to determine the effects of high- and low-dose proton pump inhibitor therapy with and without low-dose aspirin as Barrett's oesophagus chemoprevention.
Jankowski
J
J
Digestive Diseases Centre, Department of Cancer and Molecular Medicine, Medical School at Royal Infirmary, Leicester, UK. j.jankowski@le.ac.uk
Sharma
P
P
D000230:Adenocarcinoma / Q000188:drug therapy; D001471:Barrett Esophagus / Q000188:drug therapy*; D016099:Endoscopy, Gastrointestinal / Q000379:methods; D004938:Esophageal Neoplasms / Q000188:drug therapy; D004941:Esophagitis / Q000150:complications; D005753:Gastric Mucosa; D005764:Gastroesophageal Reflux / Q000601:surgery; D006801:Humans; D010778:Photochemotherapy / Q000379:methods; D054328:Proton Pump Inhibitors
D054328:Proton Pump Inhibitors